Jennison Associates LLC Has $1.01 Billion Stake in AstraZeneca PLC (NASDAQ:AZN)

Jennison Associates LLC boosted its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 3.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,430,963 shares of the company’s stock after purchasing an additional 466,416 shares during the period. Jennison Associates LLC’s holdings in AstraZeneca were worth $1,011,037,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the business. Martin Investment Management LLC raised its position in AstraZeneca by 2.8% in the 3rd quarter. Martin Investment Management LLC now owns 284,204 shares of the company’s stock worth $22,571,000 after purchasing an additional 7,615 shares during the last quarter. Nordea Investment Management AB acquired a new position in shares of AstraZeneca during the fourth quarter valued at $754,000. Diversify Wealth Management LLC increased its position in AstraZeneca by 3.6% in the fourth quarter. Diversify Wealth Management LLC now owns 4,402 shares of the company’s stock worth $295,000 after purchasing an additional 153 shares during the period. Ameritas Advisory Services LLC lifted its position in AstraZeneca by 25.9% during the 4th quarter. Ameritas Advisory Services LLC now owns 9,487 shares of the company’s stock valued at $622,000 after purchasing an additional 1,949 shares during the period. Finally, Integrated Advisors Network LLC boosted its stake in shares of AstraZeneca by 46.6% in the 3rd quarter. Integrated Advisors Network LLC now owns 43,610 shares of the company’s stock valued at $3,398,000 after purchasing an additional 13,860 shares during the last quarter. Institutional investors own 20.35% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently weighed in on AZN. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. UBS Group raised AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday, November 20th. Two analysts have rated the stock with a hold rating, five have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat, AstraZeneca presently has an average rating of “Buy” and an average price target of $89.75.

AstraZeneca Stock Performance

Shares of AstraZeneca stock opened at $70.76 on Monday. AstraZeneca PLC has a 12 month low of $60.47 and a 12 month high of $87.68. The company has a current ratio of 0.93, a quick ratio of 0.71 and a debt-to-equity ratio of 0.71. The company has a market capitalization of $219.43 billion, a PE ratio of 33.86, a PEG ratio of 1.18 and a beta of 0.46. The stock’s fifty day simple moving average is $67.08 and its 200 day simple moving average is $73.85.

AstraZeneca (NASDAQ:AZN) last released its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 earnings per share for the quarter, beating the consensus estimate of $1.01 by $0.03. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The business had revenue of $13.57 billion for the quarter, compared to analysts’ expectations of $13.08 billion. During the same quarter in the previous year, the business posted $0.87 EPS. AstraZeneca’s revenue for the quarter was up 18.0% on a year-over-year basis. On average, research analysts predict that AstraZeneca PLC will post 4.13 EPS for the current year.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.